LIG1 and cancer: Using a CRISPR/Cas9‐based combined screening approach that integrates RNAi with CRISPRn and CRISPRi, researchers identified DNA ligase I (LIG1) as a novel synthetic lethal target in BRCA1‐mutant cancers.139